Article
Evaluation of anti-lived and anti-fixed- Leishmania (Viannia) braziliensis promastigotes IgG antibodies detected by flow cytometry for diagnosis and post-therapeutic cure assessment in localized cutaneous leishmaniasis
Registro en:
PEREIRA, Valéria Rêgo Alves et al. Evaluation of anti-lived and anti-fixed- Leishmania (Viannia) braziliensis promastigotes IgG antibodies detected by flow cytometry for diagnosis and post-therapeutic cure assessment in localized cutaneous leishmaniasis. Diagnostic Microbiology and Infectious Disease. 2012, vol.74, pp. 292-298
10.1016/j.diagmicrobio.2012.06.025
Autor
Pereira, Valéria Rêgo Alves
Reis, Luiza de Campos
Souza, Marina de Assis
Oliveira, Andresa Pereira de
Brito, Maria Edileuza Felinto de
Lage, Paula Souza
Andrade, Mariléia Chaves de
Rocha, Roberta Dias Rodrigues
Martins Filho, Olindo Assis
Resumen
State of Pernambuco Research Foundation (FACEPE), by the Brazilian National Research Council (CNPq), and by the Oswaldo Cruz Foundation (FIOCRUZ). This study aims to investigate a flow cytometry performance–based methodology to detect anti-live (FC-ALPA-IgG) and anti-fixed (FC-AFPA-IgG) Leishmania (Viannia) braziliensis promastigote IgG as a means to monitor post-therapeutic cure of patients with localized cutaneous leishmaniasis (LCL). Serum samples from 30 LCL patients infected with L. (V.) braziliensis were assayed, comparing the IgG reactivity before and after specific treatment with pentavalent antimonial. Reactivities were reported as the percentage of positive fluorescent parasites (PPFP), using a PPFP of 60% as a cut-off value. In the serum dilution of 1:1024, the positive percentage of LCL serum sample for FC-ALPA-IgG and FC-AFPA-IgG was 86% and 90%, respectively, before treatment. Analysis of ∆PPFP that represents the difference between PPFP after and before treatment appeared as a new approach to monitor post-therapeutic IgG reactivity in LCL. Our data support the perspective of using FC-ALPA and FC-AFPA as a useful serologic tool for diagnosis and for post-therapeutic follow-up of LCL patients.